BriaCell Retained Earnings vs Total Assets Analysis

BCTXW Stock  USD 0.34  0.03  9.68%   
BriaCell Therapeutics financial indicator trend analysis is way more than just evaluating BriaCell Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BriaCell Therapeutics is a good investment. Please check the relationship between BriaCell Therapeutics Retained Earnings and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BriaCell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Retained Earnings vs Total Assets

Retained Earnings vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BriaCell Therapeutics Retained Earnings account and Total Assets. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between BriaCell Therapeutics' Retained Earnings and Total Assets is -0.33. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Total Assets in the same time period over historical financial statements of BriaCell Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of BriaCell Therapeutics' Retained Earnings and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of BriaCell Therapeutics Corp are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Retained Earnings i.e., BriaCell Therapeutics' Retained Earnings and Total Assets go up and down completely randomly.

Correlation Coefficient

-0.33
Relationship DirectionNegative 
Relationship StrengthInsignificant

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Total Assets

Total assets refers to the total amount of BriaCell Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BriaCell Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from BriaCell Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BriaCell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BriaCell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
At this time, BriaCell Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 8.4 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.62) in 2024.
 2021 2022 2023 2024 (projected)
Interest Income136.7K891.2K1.0M1.1M
Research Development8.0M15.3M27.2M28.5M

BriaCell Therapeutics fundamental ratios Correlations

-0.10.79-0.98-0.33-0.010.98-0.04-0.090.980.450.540.70.520.980.02-0.15-0.050.090.350.42-0.440.79-0.080.97-0.57
-0.1-0.290.17-0.750.93-0.18-0.080.93-0.190.68-0.070.010.12-0.140.90.2-0.23-0.930.220.41-0.53-0.240.93-0.27-0.59
0.79-0.29-0.80.18-0.20.80.09-0.210.8-0.06-0.060.87-0.10.77-0.26-0.180.110.22-0.140.17-0.130.98-0.20.78-0.21
-0.980.17-0.80.240.11-1.00.190.19-1.0-0.37-0.52-0.65-0.49-1.00.090.10.18-0.18-0.3-0.430.42-0.830.17-0.990.55
-0.33-0.750.180.24-0.79-0.240.13-0.7-0.23-0.98-0.56-0.06-0.7-0.3-0.860.030.260.72-0.66-0.520.650.13-0.71-0.20.79
-0.010.93-0.20.11-0.79-0.110.020.99-0.120.75-0.030.080.13-0.070.97-0.16-0.13-0.990.20.27-0.42-0.170.99-0.19-0.53
0.98-0.180.8-1.0-0.24-0.11-0.19-0.191.00.360.520.650.491.0-0.1-0.1-0.180.180.30.44-0.430.83-0.180.99-0.54
-0.04-0.080.090.190.130.02-0.190.04-0.19-0.13-0.170.27-0.19-0.20.01-0.220.98-0.03-0.2-0.330.32-0.120.04-0.190.25
-0.090.93-0.210.19-0.70.99-0.190.04-0.20.67-0.150.060.02-0.150.93-0.16-0.11-0.990.090.24-0.37-0.181.0-0.27-0.45
0.98-0.190.8-1.0-0.23-0.121.0-0.19-0.20.350.520.650.491.0-0.11-0.11-0.180.190.290.43-0.420.83-0.180.99-0.53
0.450.68-0.06-0.37-0.980.750.36-0.130.670.350.620.110.730.420.81-0.14-0.24-0.680.610.49-0.63-0.020.680.32-0.79
0.54-0.07-0.06-0.52-0.56-0.030.52-0.17-0.150.520.62-0.090.980.560.11-0.03-0.160.130.710.34-0.37-0.03-0.140.56-0.46
0.70.010.87-0.65-0.060.080.650.270.060.650.11-0.09-0.080.640.06-0.110.24-0.080.10.11-0.130.810.070.62-0.27
0.520.12-0.1-0.49-0.70.130.49-0.190.020.490.730.98-0.080.540.270.04-0.22-0.040.760.42-0.48-0.070.030.51-0.59
0.98-0.140.77-1.0-0.3-0.071.0-0.2-0.151.00.420.560.640.54-0.04-0.1-0.190.150.370.45-0.450.8-0.140.99-0.57
0.020.9-0.260.09-0.860.97-0.10.010.93-0.110.810.110.060.27-0.04-0.14-0.13-0.930.410.3-0.45-0.230.93-0.15-0.57
-0.150.2-0.180.10.03-0.16-0.1-0.22-0.16-0.11-0.14-0.03-0.110.04-0.1-0.14-0.210.120.120.25-0.24-0.16-0.15-0.14-0.22
-0.05-0.230.110.180.26-0.13-0.180.98-0.11-0.18-0.24-0.160.24-0.22-0.19-0.13-0.210.13-0.23-0.410.41-0.1-0.11-0.170.35
0.09-0.930.22-0.180.72-0.990.18-0.03-0.990.19-0.680.13-0.08-0.040.15-0.930.120.13-0.13-0.220.360.19-0.990.260.45
0.350.22-0.14-0.3-0.660.20.3-0.20.090.290.610.710.10.760.370.410.12-0.23-0.130.28-0.35-0.10.10.33-0.46
0.420.410.17-0.43-0.520.270.44-0.330.240.430.490.340.110.420.450.30.25-0.41-0.220.28-0.980.260.230.38-0.79
-0.44-0.53-0.130.420.65-0.42-0.430.32-0.37-0.42-0.63-0.37-0.13-0.48-0.45-0.45-0.240.410.36-0.35-0.98-0.21-0.37-0.370.87
0.79-0.240.98-0.830.13-0.170.83-0.12-0.180.83-0.02-0.030.81-0.070.8-0.23-0.16-0.10.19-0.10.26-0.21-0.180.81-0.27
-0.080.93-0.20.17-0.710.99-0.180.041.0-0.180.68-0.140.070.03-0.140.93-0.15-0.11-0.990.10.23-0.37-0.18-0.25-0.47
0.97-0.270.78-0.99-0.2-0.190.99-0.19-0.270.990.320.560.620.510.99-0.15-0.14-0.170.260.330.38-0.370.81-0.25-0.48
-0.57-0.59-0.210.550.79-0.53-0.540.25-0.45-0.53-0.79-0.46-0.27-0.59-0.57-0.57-0.220.350.45-0.46-0.790.87-0.27-0.47-0.48
Click cells to compare fundamentals

BriaCell Therapeutics Account Relationship Matchups

BriaCell Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets478.3K58.0M42.6M27.2M5.9M10.3M
Total Current Liabilities3.6M556.8K941.1K1.8M7.5M7.8M
Total Stockholder Equity(3.3M)57.3M10.3M(3.8M)(2.4M)(2.3M)
Net Debt209.3K(57.2M)(41.0M)(21.3M)(862.1K)(905.2K)
Retained Earnings(16.6M)(15.8M)(60.3M)(80.7M)(85.4M)(81.2M)
Accounts Payable4.2K214.1K463.3K1.1M7.2M7.5M
Cash19.5K57.3M41.0M21.3M862.1K819.0K
Non Current Assets Total238.9K245.6K230.3K215.1K2.2M1.2M
Cash And Short Term Investments19.5K57.3M41.0M21.3M862.1K819.0K
Common Stock Shares Outstanding713.9K4.5M15.5M15.5M16.5M17.3M
Liabilities And Stockholders Equity478.3K58.0M42.6M27.2M5.9M10.3M
Non Current Liabilities Total142.8K225.4K31.3M29.1M1.1M1.0M
Other Stockholder Equity2.2M31.8M5.2M7.4M11.0M7.7M
Total Liab3.8M782.2K32.2M30.9M8.6M4.8M
Total Current Assets239.4K57.8M42.3M26.9M3.7M3.5M
Net Receivables20.6K12.6K24.1K717.7K1.4M1.4M
Other Current Liab3.4M342.7K477.8K677.7K290.4K275.9K
Inventory(305.0)1.0(24.1K)(18.9K)(1.4M)(1.3M)
Other Current Assets199.7K516.9K1.3M5.0M1.4M721.5K
Accumulated Other Comprehensive Income(81.0K)(94.5K)(127.0K)(138.7K)(124.8K)(118.6K)
Intangible Assets238.9K245.6K230.3K215.1K199.8K182.9K
Net Invested Capital(4.1M)57.3M10.3M(3.8M)(2.4M)(2.3M)
Net Working Capital(4.5M)57.2M41.4M25.1M(3.8M)(3.6M)
Capital Stock11.2M54.8M65.6M69.6M72.2M45.8M
Common Stock11.2M54.8M65.6M69.6M72.2M45.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.